TxCell
Trending Articles
Related Content
Manufacturing
TxCell completes CAR-Treg manufacturing process development
TxCell, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, announced it has completed the development of its first-generation production process for its proprietary CAR-Treg technology
Research & Development
TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells
TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement